Taken together, these multiple independent lines of evidence suggest that upregulation of Tmem30a will confer neurological benefits after stroke, but neurological benefits are notable in models of ischemia/reperfusion, not in those of permanent ischemia. This evidence concerns the gene CDC50A and stroke disorder.